Cancer Care Ontario | Cancer Care Ontario

Les statistiques sur le cancer en Ontario 2024 représentent le cinquième d'une série de rapports qui fournissent des informations approfondies sur l'...

Feb 2025

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Drug

selpercatinib

Other Name(s): Retevmo™

Quick Link(s): Drug Monograph, Patient Info Sheet

May 2025

Document

[PDF]

SerousOvarianCancerTreatmentPathwayMap.pdf

Apr 2025

Drug

atezolizumab (subcut)

Other Name(s): Tecentriq® SC

Quick Link(s): Drug Monograph, Patient Info Sheet

Jul 2025

Regimen

AVD+NIVL

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Show More Show more tags

, Show Less Show fewer tags

Intent: Curative

Drugs Used:

nivolumab (Unfunded),

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

May 2025

Document

[PDF]

Support-on-Your-Palliative-Care-Journey.pdf

New

Jun 2025

Document

[PDF]

Accompagnement-dans-votre-parcours-de-soins-palliatifs.pdf

New

Jun 2025

Safe-to-Switch.png

Systemic-Treatment-Implementation-Plan-2024-2028-EN.pdf

Systemic-Treatment-Implementation-Plan-2024-2028-FR

Standardized-Adnexal-Masses-US-Reporting-Explanatory-Notes.pdf

Statistiques sur le cancer en Ontario 2024

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

selpercatinib

SerousOvarianCancerTreatmentPathwayMap.pdf

atezolizumab (subcut)

AVD+NIVL

Support-on-Your-Palliative-Care-Journey.pdf

Accompagnement-dans-votre-parcours-de-soins-palliatifs.pdf

Pages